Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models

Archive ouverte

Thiollier, Clarisse | Lopez, Cécile | Gerby, Bastien | Ignacimouttou, Cathy | Poglio, Sandrine | Duffourd, Yannis | Guégan, Justine | Rivera-Munoz, Paola | Bluteau, Olivier | Mabialah, Vinciane | Diop, M’boyba | Wen, Qiang | Petit, Arnaud | Bauchet, Anne-Laure | Reinhardt, Dirk | Bornhauser, Beat | Gautheret, Daniel | Lécluse, Yann | Landman-Parker, Judith | Radford, Isabelle | Vainchenker, William | Dastugue, Nicole | de Botton, Stephane | Dessen, Philippe | Bourquin, Jean-Pierre | Crispino, John | Ballerini, Paola | Bernard, Olivier | Pflumio, Francoise | Mercher, Thomas

Edité par CCSD ; Rockefeller University Press -

International audience. Acute megakaryoblastic leukemia (AMKL) is a heterogeneous disease generally associated with poor prognosis. Gene expression profiles indicate the existence of distinct molecular subgroups, and several genetic alterations have been characterized in the past years, including the t(1;22)(p13;q13) and the trisomy 21 associated with GATA1 mutations. However, the majority of patients do not present with known mutations, and the limited access to primary patient leukemic cells impedes the efficient development of novel therapeutic strategies. In this study, using a xenotransplantation approach, we have modeled human pediatric AMKL in immunodeficient mice. Analysis of high-throughput RNA sequencing identified recurrent fusion genes defining new molecular subgroups. One subgroup of patients presented with MLL or NUP98 fusion genes leading to up-regulation of the HOX A cluster genes. A novel CBFA2T3-GLIS2 fusion gene resulting from a cryptic inversion of chromosome 16 was identified in another subgroup of 31% of non-Down syndrome AMKL and strongly associated with a gene expression signature of Hedgehog pathway activation. These molecular data provide useful markers for the diagnosis and follow up of patients. Finally, we show that AMKL xenograft models constitute a relevant in vivo preclinical screening platform to validate the efficacy of novel therapies such as Aurora A kinase inhibitors.

Suggestions

Du même auteur

Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia

Archive ouverte | Laurent, Anouchka | CCSD

PURPOSE: Children with Down syndrome (constitutive trisomy 21) that develop acute lymphoblastic leukemia (DS-ALL) have a 3-fold increased likelihood of treatment-related mortality coupled with a higher cumulative incidence of rela...

Identification of Regulators of Polyploidization Presents Therapeutic Targets for Treatment of AMKL

Archive ouverte | Wen, Qiang | CCSD

International audience

Activating mutations in human acute megakaryoblastic leukemia

Archive ouverte | Malinge, Sébastien | CCSD

International audience. Abstract Oncogenic activation of tyrosine kinase signaling pathway is recurrent in human leukemia. To gain insight into the oncogenic process leading to acute megakaryoblastic leukemia (AMKL)...

Chargement des enrichissements...